Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Penn Epilepsy Center, Philadelphia, Pennsylvania, USA.
Epilepsia. 2023 Jul;64(7):1862-1872. doi: 10.1111/epi.17641. Epub 2023 May 15.
Epilepsy is largely a treatable condition with antiseizure medication (ASM). Recent national administrative claims data suggest one third of newly diagnosed adult epilepsy patients remain untreated 3 years after diagnosis. We aimed to quantify and characterize this treatment gap within a large US academic health system leveraging the electronic health record for enriched clinical detail.
This retrospective cohort study evaluated the proportion of adult patients in the health system from 2012 to 2020 who remained untreated 3 years after initial epilepsy diagnosis. To identify incident epilepsy, we applied validated administrative health data criteria of two encounters for epilepsy/seizures and/or convulsions, and we required no ASM prescription preceding the first encounter. Engagement with the health system at least 2 years before and at least 3 years after diagnosis was required. Among subjects who met administrative data diagnosis criteria, we manually reviewed medical records for a subset of 240 subjects to verify epilepsy diagnosis, confirm treatment status, and elucidate reason for nontreatment. These results were applied to estimate the proportion of the full cohort with untreated epilepsy.
Of 831 patients who were automatically classified as having incident epilepsy by inclusion criteria, 80 (10%) remained untreated 3 years after incident epilepsy diagnosis. Manual chart review of incident epilepsy classification revealed only 33% (78/240) had true incident epilepsy. We found untreated patients were more frequently misclassified (p < .001). Using corrected counts, we extrapolated to the full cohort (831) and estimated <1%-3% had true untreated epilepsy.
We found a substantially lower proportion of patients with newly diagnosed epilepsy remained untreated compared to previous estimates from administrative data analysis. Manual chart review revealed patients were frequently misclassified as having incident epilepsy, particularly patients who were not treated with an ASM. Administrative data analyses utilizing only diagnosis codes may misclassify patients as having incident epilepsy.
抗癫痫药物(ASM)可有效治疗大部分癫痫。最近的全国行政索赔数据表明,三分之一的新诊断成年癫痫患者在诊断后 3 年内未接受治疗。我们旨在利用电子健康记录丰富的临床细节,在大型美国学术医疗系统中量化和描述这一治疗差距。
本回顾性队列研究评估了 2012 年至 2020 年期间,在该医疗系统中,有多少新诊断为癫痫的成年患者在首次癫痫诊断后 3 年内未接受治疗。为了确定癫痫的发病情况,我们应用了经过验证的行政健康数据标准,即两次癫痫/发作和/或抽搐就诊,且在首次就诊前无 ASM 处方。要求患者在诊断前至少 2 年和诊断后至少 3 年与医疗系统保持接触。对于符合行政数据诊断标准的患者,我们从其中随机抽取 240 名患者的病历进行人工审查,以验证癫痫诊断、确认治疗状况,并阐明未进行治疗的原因。这些结果用于估计未经治疗的癫痫患者的比例。
在 831 名符合纳入标准的自动分类为患有癫痫的患者中,有 80 名(10%)在癫痫发病后 3 年内未接受治疗。对癫痫分类的病历人工审查显示,仅有 33%(78/240)的患者真正患有新发癫痫。我们发现未接受治疗的患者被误诊的频率更高(p<0.001)。使用校正后的病例数,我们推断出在整个队列(831 名)中,<1%-3%的患者患有真正的未经治疗的癫痫。
我们发现,与之前从行政数据分析中得出的估计值相比,新诊断的癫痫患者中未接受治疗的比例要低得多。人工病历审查显示,患者经常被误诊为患有新发癫痫,尤其是未接受 ASM 治疗的患者。仅利用诊断代码进行的行政数据分析可能会将患者误诊为患有新发癫痫。